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Background: This study aims at identifying predictors of the treatment decision of German physicians with regard
to a non-nucleoside reverse transcriptase inhibitor (NNRTI) or a ritonavir-boosted protease inhibitor (PI/r) -based
initial treatment regimen.
Methods: The study is based on a sub analysis of a nation-wide multi-centre, non-interventional, prospective
cohort study. 133 patients were identified, who received antiretroviral first-line therapy. By means of a logistic
regression, factors that determine the treatment strategy for treatment-naïve patients were analysed.
Results: Compared to patients receiving a NNRTI-based initial regimen, patients treated with PI/r are slightly
younger, less educated, in a later stage of HIV and have more concomitant diseases. Regression analysis revealed
that being in a later stage of HIV (CDC-C) is significantly associated with a PI/r-based treatment decision.
Conclusions: Our analysis is the first study in Germany investigating sociodemographic and disease-specific
parameters associated with a NNRTI- or a PI/r-based initial treatment decision. The results confirm that the
treatment decision for a PI/r strategy is associated with disease severity.
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Since combination antiretroviral therapy (cART) became
available in 1996, progression to an immunodeficient
state of HIV infection can be effectively avoided, redu-
cing both mortality and morbidity associated with HIV
infection [1, 2]. In addition, by the effective reduction of
viral load, cART is able to reduce the risk of horizontal
and vertical HIV transmission [3].* Correspondence: jmahlich@its.jnj.com; mahlich@dice.hhu.de
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(http://creativecommons.org/publicdomain/zeActual guidelines for the initiation of cART in HIV-
infected individuals recommend antiretroviral regimens
consisting mainly of two nucleoside reverse transcriptase
inhibitors (nRTI) combined with either a non-nucleoside
reverse transcriptase inhibitor (NNRTI) or a ritonavir-
boosted protease inhibitor (PI/r) or, more recently, an
integrase strand transfer inhibitor (INSTI) [4, 5]. While
a recent meta-analysis did not find differences between
NNRTI- and PI/r-based regimens in terms of clinical
outcomes such as death or progression to AIDS, it was
found that trial-defined virological failure was higher
with a NNRTI-based regimen [6]. Also, toxicity of cer-
tain NNRTIs were found to be inferior to PI/r-based
regimen [7]. Hence, the 2015 updates of both thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Table 1 Variables
Treatment regimen • NNRTI-based
• PI/r-based
• Other
Sociodemographic factors
Patient age (in years) at diagnosis • < 50 years old
• 50 years or older
Education level • With college degree
• Without college degree
Anamnestic factors
HIV stage according to CDC classification • A (asymptomatic)
• B (symptomatic)
• C (AIDS-defining diseases)
More than three concomitant diseases • No
• Yes
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guidelines do not longer recommend NNRTI based regi-
mens as an preferred or unrestricted option for the initi-
ation of cART [4, 5].
Important predictors of virological failure are anti-
retroviral resistance and inadequate antiretroviral medi-
cation adherence to cART [8, 9]. Both factors are linked
in that inadequate adherence increases the risk of emer-
ging resistance against antiretroviral drugs [10] by allow-
ing HIV replication in the presence of sub-therapeutic
drug levels. Several factors, in turn, have been reported
to negatively influence treatment adherence: sociodemo-
graphic factors such as younger age [11, 12], lower in-
come [13], unemployment [14], and low educational
level [15]; treatment-related factors such as high intake
frequency [15, 16]; disease-specific factors such as ad-
vanced disease stage [17], occurrence of adverse
events [18], or the number of concomitant diseases
[19]; and physician-patient relationship factors such
as lack of mutual trust between the physician and the
patient [11, 16]. Factors related to clinical setting
such as insufficient medical health care [13] or the
absence of patient education programs [20] have been
identified as well.
Further results indicate that an impaired adherence in-
fluences medication resistance more intensively in
NNRTI-based than in PI/r-based strategies [8, 21, 22].
Moreover, NNRTI-associated resistance is associated
with an elevated morbidity and mortality [23, 24]. As a
consequence, it is assumed that people living with HIV
or AIDS (PLWHA) who do not properly adhere to their
medication are more likely to receive a PI/r- rather than
a NNRTI-based treatment regimen by their physicians
in order to prevent potential damages. Our analysis in-
tends to analyze if this conjecture holds true for the case
of German HIV specialists. Based on data of the German
‘Cost and Resource Utilisation Study in Antiretroviral
Therapy’ (CORSAR) [25], we analyze parameters that
influence PLWHA’s adherence to identify potential
predictors of the treatment decision with regard to a
NNRTI- or a PI/r-based initial treatment regimen. To
our knowledge, this is the first study that explores
this topic in Germany, while earlier work focused on
Switzerland [26] and the UK [27]. As both treatment
guidelines and the costs of medication differ signifi-
cantly between the countries, institutional differences
of the respective health care delivery systems should
be taken into account. In Germany, for instance, the
average annual medical costs for a NNRTI-based regi-
men was 25,058 Euros, while it was 38,334 Euros for
a PI/r-based regimen [28]. The high rate of medical
innovation in this indication further underlines the
need for new data that lead to a better understanding
of factors for treatment decision.Methods
The analysis is based on the “Cost and Resource Utilisa-
tion Study in Antiretroviral Therapy” (CORSAR), a
Germany-wide, multi-centre, non-interventional, pro-
spective cohort study to evaluate costs of HIV disease in
cART-treated PLWHA [22]. Inclusion criteria for COR-
SAR were confirmed HIV diagnosis, age of at least
18 years, cART at study entry, and written informed
consent. The observation period was 96 weeks between
April 2009 (first patient started) and April 2012 (last pa-
tient finished), with scheduled quarterly visits to the in-
volved physician. The CORSAR project was not meant
to include primarily treatment-naïve patients. All partici-
pants from eight private practices specialized in HIV and
four hospitals went through a six-month period with
baseline examinations. The CORSAR data set included
1154 PLWHA representing a 2.3% sample of treated
PLWHA in Germany [29, 30]. 11.5% (n = 133) of the
study population was treatment-naïve and had been in-
cluded contemporaneously with treatment start between
April 2009 and May 2010. The CORSAR survey was ap-
proved by the national regulatory authorities and local
ethics committees of all participating centers. All pa-
tients were given thorough information on the survey.
Written informed consent was obtained from all study
participants.
Our analysis is based on the treatment naive subgroup,
which represents a sample of patients in a recent and
real clinical life setting to analyse parameters determin-
ing the choice of a particular cART regimen. Baseline
data variables that are used for the analysis are reported
in Table 1.
To evaluate parameters corresponding with the treat-
ment decision, three therapy groups were established:
(1) NNRTI-based initial treatment regimen consisted of
one NNRTI, such as Efavirenz or Rilpivirine, in addition
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treatment regimen consisted of one ritonavir boosted PI
such as Atazanavir or Darunavir in addition to nucleos(-
t)ide analogues; and (3) other initial treatment regimen
such as integrase inhibitors, entry (CCR5)-inhibitors, or
nuke-sparing regimens (e.g. boosted double-PI/r ther-
apy). During the study-period the use of INSTI was less
common than in the time since 2014. As the category
“other” is rather small and quite heterogeneous, the
focus of our analysis lies on the choice between a
NNRTI- and PI/r-based regimen. While most of the var-
iables are self-explanatory, the CDC classification might
need some additional explanation. Clinical staging of
HIV disease is performed in accordance with the CDC
classification for HIV infection [31]. By definition of the
CDC classification, the staging reflects the most ad-
vanced stage of disease and does not allow a reassign-
ment to a less advanced stage, not even in cases with a
complete and stable recovery from immunodeficiency
and AIDS-defining diseases under cART.
Due to the small sample size and the limited degrees
of freedom, we decided to merge the HIV stages A and
B to come up with only two categories (non-AIDS vs.
AIDS stage).
We employed a logistic regression to identify factors
that determine the choice of the treatment strategy. De-
scriptive statistics and regression analysis were per-
formed using SPSS, Chicago; and STATA, College Park
software respectively. Based on the findings of earlier
studies on adherence that were touched upon in the
introduction, we expect that physicians assume patients
who are younger, already in a progressed stage of HIV,
and have concomitant diseases to be less adherent to
their medication. Consequently, patients with those
characteristics may be prone to receive a PI/r-based
treatment regimen because impaired adherence influ-
ences medication resistance more intensively in NNRTI-
based than in PI/r-based strategies.Table 2 Patient characteristics
NNRTI
(n = 46) [3
Sociodemographic factors
Patient age (in years) at diagnosis <50 36 [78.3%]
≥50 10 [21.7%]
Education level (college degree) No 36 [78.3%]
Yes 10 [21.7%]
Anamnestic factors
HIV stage according to CDC classification A + B 41 [89.1%]
C (AIDS) 5 [10.9%]
Three or more concomitant diseases No 37 [80.4%]
Yes 9 [19.6%]Results
Patient characteristics according to the treatment regi-
men are reported in Table 2. Compared to patients
receiving NNRTI, PI/r-treated patients are slightly youn-
ger, less educated, in a later stage of HIV and have more
concomitant diseases. For instance, only 11% of the
patients who receive an NNRTI-based treatment regi-
men are in disease stage C, while the large majority is in
either disease state A or B. On the other hand, 37% of
the patients with a PI/r-based treatment regimen have
progressed already into disease stage C. The results are
in line with the expectations, as all three variables are
frequently associated with poor adherence.
The results of the multinomial logistic regression are
reported in Table 3. The multivariate regression analysis
confirms that NNRTI and PI treatment groups differ sig-
nificantly with regard to the disease stage. Specifically,
being in advanced HIV stage C significantly increases
the likelihood of a PI/r-based regimen for initiation of
antiretroviral treatment. This variable is also slightly
significant when NNRTI and “other” treatment regimen
are compared, while PI/r and “other” treatment regimen
do not differ significantly and can be considered as
interchangeable. All other variables were not significant
due to the limited number of patients in our analysis.
Discussion
Our results confirm earlier research that observes a rela-
tively low proportion of patients with a NNRTI-based
first-line cART in Germany in comparison to other
countries [32], although most NNRTI-based treatment
regimens are significantly cheaper than PI/r-based ones.
From the 133 patients receiving antiretroviral first-line
therapy, only 34.6% received a NNRTI-based cART regi-
men. This is in contrast to countries like the UK, where
almost 75% of first-line patients are on a NNRTI-based
regimen [27]. Moreover, a survey of clinical practice in
Europe found that the NNRTI Efavirenz is mandatoryPI Other Total
4.6%] (n = 38) [28.6%] (n = 49) [36.8%] (N = 133)
34 [89.5%] 43 [87.8%] 113 [85.0%]
4 [10.5%] 6 [12.2%] 20 [15.0%]
31 [81.6%] 41 [83.7%] 108 [81.2%]
7 [18.4%] 8 [16.3%] 25 [18.8%]
24 [63.2%] 36 [73.5%] 101 [75.9%]
14 [36.8%] 13 [26.5%] 32 [24.1%]
29 [76.3%] 39 [79.6%] 105 [78.9%]
9 [23.7%] 10 [20.4%] 28 [21.1%]
Table 3 Multinomial logistic regression
Variable Odds ratio
PI/r vs
NNRTI
PI/r vs
other
NNRTI vs
other
50 years or older 0.606419 0.9194778 1.718239
(0.463) (0.904) (0.363)
College degree 0.9528552 1.187664 1.38485
(0.935) (0.768) (0.557)
AIDS 4.237344** 1.578817 0.3524308*
(0.017) (0.337) (0.073)
3 or more concomitant
diseases
0.8452713 1.20924 0.8452713
(0.817) (0.723) (0.759)
Constant 0.6384591 0.6311049 1.004598
(0.158) (0.152) (0.987)
N 84 87 95
P value in parentheses. * p < 0.10, ** p < 0.05
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clinics [33]. The early use of PI/r for treatment-naïve
patients might be a specific feature of the German
health care system. German guidelines are relatively
liberal, as they recommend a broad spectrum of both
PI/r- and NNRTI-based cART regimens as equivalent
preferred options at the time of our study [4]. Add-
itionally, there are fewer restrictions in Germany to
choose equivalent, but more expensive cART regi-
mens individually, if this is requested either by the
treating physician or by the patient. Discrete choice-
based preference studies demonstrated that the high-
est relevance for the treatment selection of German
physicians, as well as patients, was the emotional
quality of life indicated by the fact that the disease
was not obvious for other persons, as stigma is prob-
ably still an issue in Germany [34, 35]. Those results
show that German physicians also take treatment
goals other than efficacy into account, which also ex-
plains the high variation in initial treatment regimens.
When it comes to the determinants of the treat-
ment strategy, our results are in line with previous
findings as well. A large British study, for instance,
found clinic site and a prior AIDS diagnosis (CDC
stage C) were the most important factors associated
with use of a PI/r-based initial treatment regimen
[27]. Their findings indicate that in the early days of
cART, the prescription of a PI/r-based regimen was
more likely. More recently, however, NNRTIs are on
the rise mainly due to increased cost considerations.
In the framework of a multivariate analysis of a Swiss
cohort it was also found that compared with an Efa-
virenz (NNRTI) -based initial treatment, starting with
the protease inhibitor Lopinavir/r was associated with
prior AIDS and higher viral load [26].Other factors that have been identified as predictors of
treatment adherence such as the number of concomitant
diseases [19] are not associated with the treatment deci-
sion in our data, possibly due to our small sample size.
Another possible explanation is that physicians either
consider predictors of adherence other than the ones
identified in the empirical literature, or they prescribe
PI/r for reasons other than preventing drug resistance
caused by poor adherence. Alternatively, HIV physicians
are not able to predict the prospective adherence of their
patients. It was found that clinicians tend to overesti-
mate the actual adherence of their patients [36, 37]
when they were asked for a retrospective assessment.
While suggestions have been put forward to improve the
assessment of adherence by using the data of viral load
and HIV genome sequence to identify non-adherence
amongst patients under treatment [38], things get much
more difficult when it comes to the a priori assessment
of the potential adherence of previously untreated pa-
tients when initializing cART. Given the high uncer-
tainty about potential adherence of patients and the
relatively small sample size, we consider the significant
impact of the disease stage on the treatment decision as
a strong result. In fact, a recent German data analysis
confirmed our results with a much broader sample [39].
The limitation of the use of our data is the small sample
size. Moreover, in the meantime, new treatment options
have been introduced in first-line recommendations such
as integrase inhibitors. This may have altered the use of
cART in treatment-naïve subjects after the termination of
our study. Here would seem the logical starting point for a
future study.
Conclusions
Our data reflect real clinical practice of German physi-
cians on parameters corresponding with treatment deci-
sions for antiretroviral-naïve patients with regard to the
use of NNRTI or PI/r in the years 2009 to 2012. Our
analysis is the first study in Germany investigating socio-
demographic and disease-specific parameters associated
with a NNRTI- or a PI/r-based initial treatment decision.
The results confirm that the treatment decision for a PI/
r strategy is associated with disease severity. However,
future research should analyse further baseline parame-
ters in more detail. Also drug- and physician-specific
variables such as physician training should be taken into
account to better understand the underlining mechan-
ism of prescription behaviour.
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